Anxiety disorders, PTSD and OCD: systematic review of approved psychiatric medications (2008–2024) and pipeline phase III medications

Emile Tadros, Shirley Keerthana, Samar Padder, Jayant Totlani, Drew Hirsch, Daniel N Kaidbay, Lorena Contreras, Aasim Naqvi, Samuel Miles, Krista Mercado, Ashley Meyer, Sabrina Renteria, Robert N Pechnick, Itai Danovitch, Waguih William IsHak

Article Type

Review

Published

By examining the mechanisms of action, indications, efficacy, dosing and adverse effects of psychiatic medications approved by the FDA, this review seeks to evaluate the progress and future directions in the pharmacological treatment of post-traumatic stress disorder and obsessive-compulsive
disorder.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.